AllSci News
AirNexis’s AN01 improves lung function on top of bronchodilators in COPD
A dual phosphodiesterase inhibitor delivered by dry powder inhaler met its primary endpoint in a Phase IIb randomized trial in chronic obstructive pulmonary...
Windward’s TSLP mAb shows six-month asthma activity after single dose
Positive Phase II interim data from SKB378/WIN378, an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody engineered for extended half-life, have...
Intellia’s one-shot CRISPR therapy gets March 2027 FDA decision date
Cambridge, Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced that the US FDA has accepted its Biologics License Application (BLA) and...
BMS’s GPRC5D CAR-T clears registrational trial in quadruple-exposed multiple myeloma
Arlocabtagene autoleucel met the primary endpoint of overall response rate (ORR) and all key secondary endpoints in the registrational QUINTESSENTIAL Phase...
Inhibrx's OX40 agonist nearly doubles response rate versus Keytruda alone in head and neck cancer
A hexavalent OX40 agonist that has struggled to find clinical traction across the broader class has now produced the first randomized efficacy signal for an...
German researchers show AI-designed protein vehicles outperform lipid nanoparticles in RNA delivery
Researchers at Helmholtz Munich and the Technical University of Munich, led by corresponding authors Christoph Gruber, Florian Giesert, and Wolfgang Wurst,...
Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure
Two large Phase III trials of ziltivekimab, Novo Nordisk's investigational IL-6 inhibitor, have been stopped early on the recommendation of an independent...
PDS Biotech raises up to USD 22.55m to advance IL-12 immunotherapy toward Phase III in CRC
New Jersey-based PDS Biotechnology Corporation (Nasdaq: PDSB) has raised up to USD 22.55 million in a private investment in public equity (PIPE) transaction...
Amgen’s tarlatamab delivers Phase III OS win in first-line ES-SCLC maintenance
Adding tarlatamab to durvalumab maintenance produced a statistically significant and clinically meaningful improvement in overall survival in...
Moonwalk Bio raises USD 70m Series B for adipose-targeted obesity therapies
South San Francisco-based Moonwalk Biosciences has closed an oversubscribed USD 70 million Series B financing to advance a pipeline of adipose-targeted RNA...
AZ’s tozorakimab shows Phase III benefit across eosinophil levels in COPD
Full Phase III results from the previously announced positive OBERON and TITANIA trials show that AstraZeneca's IL-33 antibody tozorakimab reduced...
FDA approves AZ’s Etcamah for pre-progression switch in HR+ breast cancer
AstraZeneca has received accelerated approval from the US FDA for Etcamah (camizestrant), an oral selective estrogen receptor degrader (SERD), in...
Novartis’s pelacarsen misses Phase III endpoint despite deep Lp(a) lowering
Novartis’s pelacarsen failed to reduce major cardiovascular events in the Phase III Lp(a)HORIZON trial despite substantially lowering lipoprotein(a)...
Novartis’s Avidity-acquired del-desiran falls short in Phase III DM1 trial
The Phase III HARBOR study of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 (DM1) has failed its primary endpoint, dealing a major...
BrainChild Bio raises USD 116m to advance CAR T therapy for pediatric brain cancer
Seattle-based BrainChild Bio, Inc., a clinical-stage company developing CAR T cell therapies for central nervous system tumors, has closed a USD 116 million...
The AllSci Brief
Free, systematic R&D and deal news. Daily.